All Articles

With a strong cash runway, Nkarta pushes its off-the-shelf NK cell therapy into community clinics, setting the stage for a pivotal data reveal in 2026.

With promising early data and a robust balance sheet, Palisade Bio is advancing its targeted IBD therapy, PALI-2108, into crucial Phase 2 trials.

FutureFuel's stunning $25.6M profit swing reveals a blueprint for resilience, powered by regulatory tailwinds in biofuels and reshoring in chemicals.

Amid Q2 losses, Proficient Auto Logistics acquires Hansen & Adkins, betting big on consolidation to navigate an auto haul industry facing an 'inflection point'.

As KNOT Offshore Partners prepares its Q2 earnings report, the market watches closely. Brazil's oil surge provides a powerful tailwind amid a buyout offer.

Amplify Energy touts a major profit swing and a new stock buyback, but a look under the hood reveals a complex picture of derivative gains and real-world challenges.

With major clinical trials progressing and a $110M war chest, Orchestra BioMed is orchestrating a potential shift in cardiovascular treatment.

Toronto's Kepler Communications is betting big on optical links and on-orbit computing. A new deal with Rocket Lab signals a major escalation in the race to control space data.

Getty Images faces a liquidity crisis with soaring debt and a failed merger, raising doubts about its future despite some growth in its core business.

Metagenomi Therapeutics is on track for a pivotal 2027 clinical trial, but its advanced gene editing tech faces a market wary of high-cost cures.

Fluent's Q2 results reveal a dramatic pivot, with Commerce Media Solutions booming 90%. But can this growth and a new in-store bet outrun a stark 'going concern' warning?

New 48-week data for envudeucitinib shows 54% of patients achieved complete skin clearance, setting a new bar for oral therapies and positioning Alumis for market disruption.

Insight Molecular Diagnostics has key regulatory and reimbursement wins for its game-changing transplant test, but a high cash burn creates a high-stakes race to commercialization.

P3 Health Partners stuns Wall Street with a swing to profitability, but a deeper dive reveals one-time gains and a strategic pivot. Is this the new playbook?

Entravision's ad-tech unit soared 230% on AI, driving record profit. But with its legacy media arm in decline, can this tech pivot redefine its future?

Sumisho Air Lease reports a 98% profit drop in its first post-acquisition quarter, but accounting shifts mask a deeper strategic realignment for the lessor.

Angie O'Leary's promotion at Commercial Vehicle Group is more than a new title. It's a strategic bet on continuity to navigate a turbulent EV transition.

Amidst declining revenue and layoffs, Rapid7's new CEO is making a bold bet on a focused, AI-driven strategy. Is this the path to renewed strength?

Alico's Q3 results reveal a successful pivot from citrus giant to land developer, with profits soaring and major projects advancing. How is this changing Florida?

In a blockbuster deal with Boeing, Archer acquires key assets to build a 'physical AI' powerhouse. But with soaring losses, is it a masterstroke or a costly bet?